Deprexis for Depression
(Deprexis Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it mentions that participants should be stable on psychotropic medications. This suggests you may continue your current medications if they are stable.
How does the drug Deprexis differ from other treatments for depression?
Deprexis, also known as deprenyl or selegiline, is unique because it is a selective monoamine oxidase type B inhibitor (MAO-B inhibitor), which means it targets a specific enzyme involved in breaking down mood-related chemicals in the brain. Unlike other MAO inhibitors, it has fewer side effects and does not cause a hypertensive crisis (dangerously high blood pressure) when consuming certain foods.12345
What is the purpose of this trial?
Depressive symptoms are common among Veterans and associated with significant impairment. Timely intervention has the potential to improve mental health outcomes and restore functioning. Interventions delivered through the internet can be completed remotely at any time, and thus minimize burden on Veterans, however the research examining their utility in Veterans is limited. This proposed project will examine Deprexis, a self-guided internet-delivered intervention, which targets depressive symptoms and associated functional impairments. Interviews will be conducted to gain insight into Veterans' perceptions, needs, and preferences vis-a-vis Deprexis, with results informing a randomized controlled trial. Here an 8-week course of Deprexis will be compared to a treatment-as-usual (TAU) control condition to establish if Deprexis is acceptable and effective for Veterans with mild to moderate depressive symptoms. Veterans engaged in Deprexis are hypothesized to show improvements on measures of functioning and decreases in depressive symptoms compared to the TAU control group. The proposed work has great clinical utility, as it could provide a readily accessible, high-quality intervention for the many Veterans suffering from depressive symptoms, with the potential to improve functioning and long-term outcomes.
Research Team
Rahel R Pearson, PhD
Principal Investigator
Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX
Eligibility Criteria
This trial is for Veterans experiencing mild to moderate depression. Participants should be interested in a self-guided, internet-based intervention and available for an 8-week course. Specific eligibility criteria are not provided, but typically participants would need access to the internet and have no conditions that significantly interfere with study participation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an 8-week course of Deprexis, a self-guided internet-delivered intervention, compared to a treatment-as-usual control condition
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at baseline, post-treatment, and 8-week follow-up
Treatment Details
Interventions
- Deprexis
Deprexis is already approved in United States for the following indications:
- Mild to moderate depressive symptoms
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor